The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Autor: Maria Rosaria Gualano, Silvio Capizzi, Maria Lucia Specchia, Giuseppe La Torre, Chiara Cadeddu, Maria Luisa Di Pietro, Walter Ricciardi, Nicola Nicolotti, S Capri, Antonella Sferrazza, Flavia Kheiraoui, Maria Assunta Veneziano, Chiara De Waure
Rok vydání: 2014
Předmět:
Budgets
Genetics and Molecular Biology (all)
Drug
medicine.medical_specialty
Technology Assessment
Biomedical
Article Subject
Immunology and Microbiology (all)
Cost-Benefit Analysis
media_common.quotation_subject
Osteoporosis
MEDLINE
lcsh:Medicine
Antibodies
Monoclonal
Humanized
Biochemistry
General Biochemistry
Genetics and Molecular Biology
Strontium ranelate
Epidemiology
Biochemistry
Genetics and Molecular Biology (all)
medicine
Humans
Settore MED/42 - IGIENE GENERALE E APPLICATA
Aged
media_common
Aged
80 and over
Bone Density Conservation Agents
General Immunology and Microbiology
Cost–benefit analysis
business.industry
lcsh:R
Health Technology Assessment
Health technology
General Medicine
Middle Aged
medicine.disease
Markov Chains
Surgery
Hospitalization
Postmenopause
Treatment Outcome
Denosumab
Italy
Physical therapy
Female
business
Osteoporotic Fractures
Research Article
medicine.drug
Zdroj: BioMed Research International, Vol 2014 (2014)
BioMed Research International
ISSN: 2314-6141
2314-6133
DOI: 10.1155/2014/975927
Popis: Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the prevention of osteoporotic fractures in postmenopausal women.Method. Epidemiological, clinical, technical, economic, organizational, and ethical aspects were considered. Medical electronic databases were accessed to evaluate osteoporosis epidemiology and therapeutical approaches. A budget impact and a cost-effectiveness analyses were performed to assess economic implications. Clinical benefits and patient needs were considered with respect to organizational and ethical evaluation.Results. In Italy around four millions women are affected by osteoporosis and have a higher risk for fractures with 70,000 women being hospitalized every year. Bisphosphonates and strontium ranelate are recommended as first line treatment for the prevention of osteoporotic fractures. Denosumab is effective in reducing vertebral, nonvertebral, and hip/femoral fractures with an advantage of being administered subcutaneously every six months. The budget impact analysis estimated a reduction in costs for the National Health Service with the introduction of denosumab. Furthermore, the economic analysis demonstrated that denosumab is cost-effective in comparison to oral bisphosphonates and strontium ranelate. Denosumab can be administered in outpatients by involving General Practitioners in the management. Ethical evaluation is positive because of its efficacy and compliance.Conclusion. Denosumab could add value in the prevention of osteoporotic fractures.
Databáze: OpenAIRE
Externí odkaz: